Basic Information
Baqsimi
Regulatory Information
EMEA/H/C/003848
December 16, 2019
5
December 5, 2024
Company Information
France
Usine Saint Charles Eragny Sur Epte 60590
AMPHASTAR FRANCE PHARMACEUTICALS
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Overview Summary
Baqsimi is a medicine used to treat severe hypoglycaemia (very low blood glucose levels) in adults, adolescents, and children aged 4 years or older who have diabetes. Hypoglycaemia can occur in people with diabetes when treatments to control blood glucose cause the levels of glucose to become too low. In severe cases, it can make patients faint or become unconscious and must therefore be treated immediately. Baqsimi contains the active substance glucagon.